Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CUBT |
---|---|---|
09:42 ET | 1000 | 0.0115 |
10:04 ET | 20000 | 0.0125 |
10:45 ET | 100000 | 0.0129 |
11:41 ET | 10000 | 0.0129 |
12:14 ET | 1500 | 0.01334 |
12:21 ET | 5000 | 0.014 |
12:48 ET | 400 | 0.01275 |
12:51 ET | 112500 | 0.0125 |
02:16 ET | 24900 | 0.0138 |
02:30 ET | 50000 | 0.01275 |
02:34 ET | 58950 | 0.013 |
03:14 ET | 66050 | 0.013 |
03:15 ET | 15000 | 0.01275 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Curative Biotechnology Inc | 8.0M | -1.2x | --- |
Connect Biopharma Holdings Ltd | 57.8M | 0.0x | --- |
Kazia Therapeutics Ltd | 12.3M | -0.5x | --- |
Enzon Pharmaceuticals Inc | 7.8M | -32.3x | --- |
Galera Therapeutics Inc | 7.7M | -0.1x | --- |
Atreca Inc | 8.5M | -0.1x | --- |
Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. It is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 628.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.01 |
Book Value | $0.00 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.